


=> d l1
 L1 HAS NO ANSWERS
 L1 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8 3
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> s l1 ful
 FULL SEARCH INITIATED 08:37:38 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 11358 TO ITERATE

100.0% PROCESSED 11358 ITERATIONS
 SEARCH TIME: 00.00.01

396 ANSWERS

L3 396 SEA SSS FUL L1

=> s.l3 and pyrimid?
1065860 PYRIMID?
L8 204 L3 AND PYRIMID?

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.03	209.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.11

FILE 'CAPLUS' ENTERED AT 08:42:36 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17
FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 18
L9 7 L8

=> s 19 and py<2001
20846668 PY<2001
L10 0 L9 AND PY<2001

=> d bib abs 1-7
L10 HAS NO ANSWERS
'BIB ABS ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains data. (Default)
SIM ----- Structure Image.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains data.
SDA ----- All Structure DATA (image, attributes, connection table and map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIA), SCT, SDA, SIM, SAT, NOS:end

=> d bib abs 19 1-7

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:409505 CAPLUS
 DN 142:463612
 TI Preparation of bipiperidinyI derivatives as inhibitors of CCR5 receptors
 IN Miller, Michael W.; Scott, Jack D.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042517	A2	20050512	WO 2004-US36273	20041101
	WO 2005042517	A3	20050728		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-516954P	P	20031103		
OS	MARPAT 142:463612				
GI					




* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [M = (un)substituted-aryl, -heteroaryl, -N(alkyl)pyridone with provisions; R1, R2 and Z independently = H, alkyl, haloalkyl; R3 = H, aryl, haloalkyl, etc.; R4 = (un)substituted-aryl, -fluorenyl, -diphenylmethyl, etc.; A = H, alkyl, alkenyl] and pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of CCR5 receptors. Thus, e.g., II was prepared by coupling of III (preparation given) with N-Boc-sarcosine and subsequent treatment of the tert-Bu carbamate intermediate with 4N HCl. The activity of I was evaluated using chemotaxis and luciferase replication assays and it was revealed that selected compds. of the invention displayed IC50 values in the range of <0.1 up to 0.19 nM. I as inhibitors of CCR5 receptors should prove useful in the treatment of human immunodeficiency virus. Pharmaceutical compns. comprising I are disclosed.

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:981365 CAPLUS
 DN 141:379943
 TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
 PA Schering Corporation, USA; Pharmacoepia, Inc.
 SO U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	US 2004209878	A1	20041021	US 2004-776988	20040211
	US 2004209878	A1	20041021	US 2004-776988	20040211
PRAI	US 2002-408027P	P	20020904		
	US 2002-421959P	P	20021029		
	US 2003-654546	A2	20030903		
GI	US 2004-776988	A	20040211		




AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a

Part
III of I-III series.

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:308430 CAPLUS
DN 140:321241
TI Preparation of heteroarylaminopiperidinylpiperidines as CCR5 chemokine receptor antagonists.
IN Albert, Rainer; Cooke, Nigel Graham; Thoma, Gebhard
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2004031172 A1 20040415 WO 2003-EP11035 20031006
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT,
 LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN,
 YU, ZA, ZW
 RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
 SI, SK, TR
 CA 2501243 AA 20040415 CA 2003-2501243 20031006
 EP 1551827 A1 20050713 EP 2003-798931 20031006
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003015092 A 20050816 BR 2003-15092 20031006
 PRAI GB 2002-23223 A 20021007
 WO 2003-EP11035 W 20031006
 OS MARPAT 140:321241
 GI



AB Title compds. [I; (1) R2 = 2,4-dimethylpyridin-3-yl-N-oxide, (a) R1 = thienyl, furyl, thiazolyl, 2-methylthiazolyl, R3 = benzo[1,3]dioxolyl, (halo)phenyl; or (b) R1 = Ph substituted by SO2Me, cyano, X = CH2, R3 = Ph; or (c) R1 = Ph, X = bond, R3 = pyridyl; or (2) R2 = 2,6-dimethylphenyl, (a) R1 = pyridyl, Ph optionally substituted by CO2H, alkoxy carbonyl, 2-methylthiazolyl, indolyl, benzimidazol-2-yl; X1 = CH2, CH2CH2; R3 = (halo)phenyl; (b) R1 = Ph, X = bond, R3 = pyridyl, or R1 = 2-methylthiazolyl, X = CH2, R3 = 1-methylindolyl; (3) R2 = 2,4-dimethylpyridin-3-yl, (a) R1 = 2-methylthiazolyl, X = bond, R3 = Ph; etc.], were prepared I (R1 = 2-pyridyl; R2 = 2,4-dimethylpyridin-3-yl-N-oxide; R3 = Ph; X = null) inhibited CCR5 in a Ca2+ mobilization assay with IC50 = 29 nM.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:265849 CAPLUS
 DN 140:321371
 TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.;
 Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.;
 Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent;
 Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min;
 James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs,
 Douglas Walsh
 PA Schering Corporation, USA
 SO PCT Int. Appl., 609 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6




	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022561	A1	20040318	WO 2003-XB327555	20030903
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,	

CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
 ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
 MG, MK, MN, MX, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG,
 SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-408027P P 20020904

US 2002-421959P P 20021029

GI



AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a

Part
 III of I-III series.

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:196486 CAPLUS

DN 140:368098

TI Orally Bioavailable Competitive CCR5 Antagonists



AU Thoma, Gebhard; Nuninger, Francois; Schaefer, Marc; Akyel, Kayhan G.; Albert, Rainer; Beerli, Christian; Bruns, Christian; Francotte, Eric; Luyten, Marcel; MacKenzie, Duncan; Oberer, Lukas; Streiff, Markus B.; Wagner, Trixie; Walter, Hansrudolf; Weckbecker, Gisbert; Zerwes, Hans-Guenter

CS Novartis Institutes for BioMedical Research, Basel, CH-4056, Switz.
 SO Journal of Medicinal Chemistry (2004), 47(8), 1939-1955
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of potential therapeutic value for the disorders mentioned above and HIV infection. Here we report on the structure-activity relationship of a new series of highly potent and selective competitive CCR5 antagonists. While all compds. tested were inactive on rodent CCR5, this series includes compds. that cross-react with the cynomolgus monkey (cyno) receptor. One of these compds., i.e., 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:202634 CAPLUS
 DN 138:238191
 TI Preparation of 1-[1-(pyrimidin-5-ylcarbonyl)piperidin-4-yl]piperidin-4-
 amines as CCR5 antagonists
 IN Palani, Anandan; Miller, Michael W.; Scott, Jack D.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020716	A1	20030313	WO 2002-US27389	20020828
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2457861	AA	20030313	CA 2002-2457861	20020828
	US 2004010008	A1	20040115	US 2002-229466	20020828
	EP 1421075	A1	20040526	EP 2002-766142	20020828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012108	A	20040824	BR 2002-12108	20020828
	CN 1551877	A	20041201	CN 2002-816679	20020828
	JP 2005502682	T2	20050127	JP 2003-524986	20020828
	US 2004092745	A1	20040513	US 2003-628933	20030729
	US 2004092551	A1	20040513	US 2003-629466	20030729
	ZA 2004001594	A	20041124	ZA 2004-1594	20040225
	NO 2004001266	A	20040326	NO 2004-1266	20040326
PRAI	US 2001-315683P	P	20010829		
	US 2002-229466	A3	20020828		
	WO 2002-US27389	W	20020828		
OS	MARPAT 138:238191				
GI					



AB The title compds. [I; R1 = piperidinyl, Ph, etc.; R2 = CH2Ph, 4-pyridylmethyl, etc.; R3 = 4,6-dimethylpyrimidine-5-yl, Ph, etc.; R9, R10, B = H, alkyl, haloalkyl; A = H, alkyl, alkenyl] and their pharmaceutically acceptable salts, useful, alone or in combination with another agent, in the treatment of Human Immunodeficiency Virus (HIV), solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis, were prepared E.g., a 6-step synthesis of II, starting from 4-hydroxypiperidine and N-Boc-4-piperidone, which showed IC50 of 1.7 nM in luciferase HIV replication assay, was given.




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:793604 CAPLUS
DN 137:310816
TI Preparation of bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
IN Albert, Rainer; Bruns, Christian; Nuninger, Francois; Streiff, Markus; Thoma, Gebhard; Zerwes, Hans-Guenter
PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002081449	A1	20021017	WO 2002-EP3871	20020408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,
 LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG,
 SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, TR

CA 2439241	AA	20021017	CA 2002-2439241	20020408
EP 1379504	A1	20040114	EP 2002-730122	20020408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1501915	A	20040602	CN 2002-807950	20020408
BR 2002008741	A	20040622	BR 2002-8741	20020408
JP 2004525174	T2	20040819	JP 2002-579437	20020408
NZ 528712	A	20050729	NZ 2002-528712	20020408
ZA 2003006432	A	20040604	ZA 2003-6432	20030819
US 2004142920	A1	20040722	US 2003-472653	20030922
NO 2003004324	A	20030926	NO 2003-4324	20030926
PRAI GB 2001-8876	A	20010409		
WO 2002-EP3871	W	20020408		
OS MARPAT 137:310816				
GI				



AB Piperidine derivs. I [X = bond, CH₂, CH₂CH₂, CHR₉, CO, O, NH, NR₉; R₁ = R₁₀- and/or R₁₁-substituted Ph, heteroaryl, heteroaryl N-oxide, naphthyl; R₂ = R₁, R₁₀- and/or R₁₁-substituted fluorenyl or R₁₀-substituted C1-6-alkyl, C2-6-alkenyl, C3-6-cycloalkyl, adamantyl, C4-8-cycloalkenyl; R₃ = R₂; R₁XNR₃ = optionally R₁₀-substituted Z; A = CH₂, NH, NR₉, S, SO, SO₂, O; n = 0 - 2; R₄, R₆ = R₅, CN, OH, OR₉, F, Cl, Br, I; R₅, R₇ = H, C1-6-alkyl, C1-6-hydroxyalkyl, C2-6-alkoxyalkyl, C1-6-haloalkyl, Ph, CH₂Ph, heteroaryl; R₈ = H, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, Ph, CH₂Ph, CN, CH₂NH₂, CH₂NHR₉, CH₂N(R₉)₂, CH₂NHCOR₉, CH₂NR₉COR₉, CH₂NHCONHR₉, CH₂NR₉CONHR₉, CH₂NR₉CON(R₉)₂, CH₂NHCO₂R₉, CH₂NR₉CO₂R₉, CH₂NHSO₂R₉, CH₂N(SO₂R₉)₂, CH₂NR₉SO₂R₉; R₉ = C1-6-alkyl, C3-6-cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, Ph, CH₂Ph, heteroaryl, CF₃] and their pharmaceutically acceptable salts, have interesting pharmaceutical properties, e.g., as CCR5 inhibitors. Piperidine derivs. I [R₁₀ = C1-6-alkyl, C1-6-hydroxyalkyl, C2-6-alkoxyalkyl, C1-6-haloalkyl, C3-6-cycloalkyl, C2-6-alkenyl, C2-6-cycloalkenyl, C2-6-alkynyl, Ph, heteroaryl, heteroaryl N-oxide, F, Cl, Br, I, OH, OR₉, CONH₂, CONHR₉, CON(R₉)₂, OC(:O)R₉, OCO₂R₉, OC(:O)NHR₉, OC(:O)NHR₉, OC(:O)N(R₉)₂, OSO₂R₉, CO₂H, CO₂R₉, CF₃, CHF₂, CH₂F, CN, NO₂, NH₂, NHR₉, N(R₉)₂, NHCOR₉, NR₉COR₉, NHCONHR₉, NHCONH₂, NR₉CONHR₉, NR₉CON(R₉)₂, NHCO₂R₉, NR₉CO₂R₉, NHSO₂R₉, N(SO₂R₉)₂, NR₉SO₂R₉, SiMe₃, B(OCMe₃); R₁₁ = two adjacent substituents which form an annulated 4 - 7 membered ring containing up to two heteroatoms of the group N, O, S; Y = bond, CO, COCH₂, SO, SO₂, CS, CH₂, C(CH₂CH₂), CHR₅, C(R₄)₂] have

interesting pharmaceutical properties, e.g., their use as chemokine receptors inhibitors. A process for the preparation of I comprises; (a) amidating I (YR2 = H) with R2Y'A' [Y' = CO, COCH2, SO, SO2]; A' = leaving group, e.g., Cl, Br, OH; (b) reductive amidation of I (YR2 = H); or (c) reacting I (XR1 = H) with R1X"-halogen (X" = CH2, CHR9). Thus, bipiperidinylbenzamide II (Y = CO, R2 = C6H3Me2-2,6) was prepared from bipiperidinamine I (Y = bond, R2 = H) and 2,6-Me2C6H3COCl in DMF containing EtN(CHMe2)2 and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate. Bipiperidinamines I were tested as chemokine receptor inhibitors [IC50 = 2 - 3 nM vs. [I-125]MIP-1 α binding to human CCR5 membrane for I (R1 = R3 = Ph, R2 = C6H4Me2-2,6, R4 - R7 = H, R8 = Me, X = CH2, Y = C:O); IC50 = 10 μ M vs. Ca2+ mobilization for II; chemotaxis by I in presence of MIP-1 α , IC50 = \leq 1 μ M].

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 7

L10 HAS NO ANSWERS

'HITSTR' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ----- Structure Image, Attributes, and map table if it contains data. (Default)

SIM ----- Structure Image.

SAT ----- Structure ATtributes and map table if it contains data.

SCT ----- Structure Connection Table and map table if it contains data.

SDA ----- All Structure DATA (image, attributes, connection table and map table if it contains data).

NOS ----- NO Structure data.

ENTER STRUCTURE FORMAT (SIA), SCT, SDA, SIM, SAT, NOS:end

=> d hitstr 19 7

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

IT 470689-17-9P 470689-20-4P 470689-21-5P

470689-23-7P 470689-27-1P 470689-32-8P

470689-43-1P 470689-57-7P 470689-60-2P

470689-61-3P 470689-72-6P 470689-77-1P

470689-78-2P 470689-79-3P 470689-81-7P


470689-85-1P 470689-86-2P 470689-90-8P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bipiperidinyl-derivs. and their use as chemokine receptors inhibitors)


RN 470689-17-9 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 4'-methyl-1'-[(4-methyl-5-pyrimidinyl)carbonyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-20-4 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-21-5 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[(4,6-dimethyl-2-phenyl-5-pyrimidinyl)carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-23-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[[4,6-dimethyl-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-27-1 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[(4,6-dimethyl-1-oxido-5-pyrimidinyl)carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-32-8 CAPLUS


CN [1,4'-Bipiperidin]-4-amine, 4'-methyl-N,N-diphenyl-1'--[(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 470689-43-1 CAPLUS
 CN [1,4'-Bipiperidin]-4-amine, 1'-[[4,6-dimethyl-2-(1-oxido-4-pyridinyl)-5-pyrimidinyl]carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-57-7 CAPLUS
 CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)



RN 470689-60-2 CAPLUS
 CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-1-oxido-5-pyrimidinyl)carbonyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-61-3 CAPLUS
 CN [1,4'-Bipiperidin]-4-amine, 1'-[[4,6-dimethyl-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-72-6 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 470689-77-1 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[(4,6-dimethyl-1-oxido-5-pyrimidinyl)carbonyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 470689-78-2 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[[4,6-dimethyl-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 470689-79-3 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[[4,6-dimethyl-2-(1-oxido-4-pyridinyl)-5-pyrimidinyl]carbonyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 470689-81-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-N-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 470689-85-1 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-1-oxido-5-pyrimidinyl)carbonyl]-N-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 470689-86-2 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4'-methyl-N-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 470689-90-8 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4'-methyl-N-phenyl- (9CI) (CA INDEX NAME)



=> s l3 and pyrimid?
1065860 PYRIMID?
L8 204 L3 AND PYRIMID?

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.03	209.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.11

FILE 'CAPLUS' ENTERED AT 08:42:36 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17
FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l8
L9 7 L8

=> s l9 and py<2001
20846668 PY<2001
L10 0 L9 AND PY<2001

=> d bib abs 1-7
L10 HAS NO ANSWERS
'BIB ABS ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains data. (Default)
SIM ----- Structure IMAge.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains data.
SDA ----- All Structure DATA (image, attributes, connection table and map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIA), SCT; SDA, SIM, SAT, NOS:end

=> d bib abs 19 1-7

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:409505 CAPLUS
 DN 142:463612
 TI Preparation of bipiperidinyl derivatives as inhibitors of CCR5 receptors
 IN Miller, Michael W.; Scott, Jack D.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042517	A2	20050512	WO 2004-US36273	20041101
	WO 2005042517	A3	20050728		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-516954P P 20031103
 OS MARPAT 142:463612
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [M = (un)substituted-aryl, -heteroaryl, -N(alkyl)pyridone with provisions; R1, R2 and Z independently = H, alkyl, haloalkyl; R3 = H, aryl, haloalkyl, etc.; R4 = (un)substituted-aryl, -fluorenyl, -diphenylmethyl, etc.; A = H, alkyl, alkenyl] and pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of CCR5 receptors. Thus, e.g., II was prepared by coupling of III (preparation given) with N-Boc-sarcosine and subsequent treatment of the tert-Bu carbamate intermediate with 4N HCl. The activity of I was evaluated using chemotaxis and luciferase replication assays and it was revealed that selected compds. of the invention displayed IC50 values in the range of <0.1 up to 0.19 nM. I as inhibitors of CCR5 receptors should prove useful in the treatment of human immunodeficiency virus. Pharmaceutical compns. comprising I are disclosed.

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:981365 CAPLUS
 DN 141:379943
 TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
 PA Schering Corporation, USA; Pharmacopeia, Inc.
 SO U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
 CODEN: USXXCO




DT Patent
 LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	US 2004209878	A1	20041021	US 2004-776988	20040211
	US 2004209878	A1	20041021	US 2004-776988	20040211
PRAI	US 2002-408027P	P	20020904		
	US 2002-421959P	P	20021029		
	US 2003-654546	A2	20030903		
	US 2004-776988	A	20040211		

GI




AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a

Part
III of I-III series.

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:308430 CAPLUS
 DN 140:321241
 TI Preparation of heteroarylaminopiperidinylpiperidines as CCR5 chemokine receptor antagonists.
 IN Albert, Rainer; Cooke, Nigel Graham; Thoma, Gebhard
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 PI WO 2004031172 A1 20040415 WO 2003-EP11035 20031006
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT,
 LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN,
 YU, ZA, ZW
 RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
 SI, SK, TR
 CA 2501243 AA 20040415 CA 2003-2501243 20031006
 EP 1551827 A1 20050713 EP 2003-798931 20031006
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003015092 A 20050816 BR 2003-15092 20031006
 PRAI GB 2002-23223 A 20021007
 WO 2003-EP11035 W 20031006
 OS MARPAT 140:321241
 GI



AB Title compds. [I; (1) R2 = 2,4-dimethylpyridin-3-yl-N-oxide, (a) R1 = thienyl, furyl, thiazolyl, 2-methylthiazolyl, R3 = benzo[1,3]dioxolyl, (halo)phenyl; or (b) R1 = Ph substituted by SO2Me, cyano, X = CH2, R3 = Ph; or (c) R1 = Ph, X = bond, R3 = pyridyl; or (2) R2 = 2,6-dimethylphenyl, (a) R1 = pyridyl, Ph optionally substituted by CO2H, alkoxycarbonyl, 2-methylthiazolyl, indolyl, benzimidazol-2-yl; X1 = CH2, CH2CH2; R3 = (halo)phenyl; (b) R1 = Ph, X = bond, R3 = pyridyl, or R1 = 2-methylthiazolyl, X = CH2, R3 = 1-methylindolyl; (3) R2 = 2,4-dimethylpyridin-3-yl, (a) R1 = 2-methylthiazolyl, X = bond, R3 = Ph; etc.], were prepared I (R1 = 2-pyridyl; R2 = 2,4-dimethylpyridin-3-yl-N-oxide; R3 = Ph; X = null) inhibited CCR5 in a Ca2+ mobilization assay with IC50 = 29 nM.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:265849 CAPLUS
 DN 140:321371
 TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
 PA Schering Corporation, USA
 SO PCT Int. Appl., 609 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6




	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022561	A1	20040318	WO 2003-XB327555	20030903
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,	

CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
 ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
 MG, MK, MN, MX, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG,
 SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-408027P P 20020904

US 2002-421959P P 20021029

GI



AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a

Part

III of I-III series.

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:196486 CAPLUS

DN 140:368098

TI Orally Bioavailable Competitive CCR5 Antagonists

AU Thoma, Gebhard; Nuninger, Francois; Schaefer, Marc; Akyel, Kayhan G.; Albert, Rainer; Beerli, Christian; Bruns, Christian; Francotte, Eric; Luyten, Marcel; MacKenzie, Duncan; Oberer, Lukas; Streiff, Markus B.; Wagner, Trixie; Walter, Hansrudolf; Weckbecker, Gisbert; Zerwes, Hans-Guenter

CS Novartis Institutes for BioMedical Research, Basel, CH-4056, Switz.
 SO Journal of Medicinal Chemistry (2004), 47(8), 1939-1955
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of potential therapeutic value for the disorders mentioned above and HIV infection. Here we report on the structure-activity relationship of a new series of highly potent and selective competitive CCR5 antagonists. While all compds. tested were inactive on rodent CCR5, this series includes compds. that cross-react with the cynomolgus monkey (cyno) receptor. One of these compds., i.e., 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:202634 CAPLUS
 DN 138:238191
 TI Preparation of 1-[1-(pyrimidin-5-ylcarbonyl)piperidin-4-yl]piperidin-4-
 amines as CCR5 antagonists
 IN Palani, Anandan; Miller, Michael W.; Scott, Jack D.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020716	A1	20030313	WO 2002-US27389	20020828
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2457861	AA	20030313	CA 2002-2457861	20020828
	US 2004010008	A1	20040115	US 2002-229466	20020828
	EP 1421075	A1	20040526	EP 2002-766142	20020828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012108	A	20040824	BR 2002-12108	20020828
	CN 1551877	A	20041201	CN 2002-816679	20020828
	JP 2005502682	T2	20050127	JP 2003-524986	20020828
	US 2004092745	A1	20040513	US 2003-628933	20030729
	US 2004092551	A1	20040513	US 2003-629466	20030729
	ZA 2004001594	A	20041124	ZA 2004-1594	20040225
	NO 2004001266	A	20040326	NO 2004-1266	20040326
PRAI	US 2001-315683P	P	20010829		
	US 2002-229466	A3	20020828		
	WO 2002-US27389	W	20020828		
OS	MARPAT 138:238191				
GI					



AB The title compds. [I; R1 = piperidinyll, Ph, etc.; R2 = CH2Ph, 4-pyridylmethyl, etc.; R3 = 4,6-dimethylpyrimidine-5-yl, Ph, etc.; R9, R10, B = H, alkyl, haloalkyl; A = H, alkyl, alkenyl] and their pharmaceutically acceptable salts, useful, alone or in combination with another agent, in the treatment of Human Immunodeficiency Virus (HIV), solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis, were prepared E.g., a 6-step synthesis of II, starting from 4-hydroxypiperidine and N-Boc-4-piperidone, which showed IC50 of 1.7 nM in luciferase HIV replication assay, was given.




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:793604 CAPLUS
DN 137:310816
TI Preparation of bipiperidinyll-derivatives and their use as chemokine receptors inhibitors
IN Albert, Rainer; Bruns, Christian; Nuninger, Francois; Streiff, Markus; Thoma, Gebhard; Zerwes, Hans-Guenter
PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002081449	A1	20021017	WO 2002-EP3871	20020408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,
 LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG,
 SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, TR

CA 2439241	AA	20021017	CA 2002-2439241	20020408
EP 1379504	A1	20040114	EP 2002-730122	20020408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1501915	A	20040602	CN 2002-807950	20020408
BR 2002008741	A	20040622	BR 2002-8741	20020408
JP 2004525174	T2	20040819	JP 2002-579437	20020408
NZ 528712	A	20050729	NZ 2002-528712	20020408
ZA 2003006432	A	20040604	ZA 2003-6432	20030819
US 2004142920	A1	20040722	US 2003-472653	20030922
NO 2003004324	A	20030926	NO 2003-4324	20030926
PRAI GB 2001-8876	A	20010409		
WO 2002-EP3871	W	20020408		
OS MARPAT 137:310816				
GI				



AB Piperidine derivs. I [X = bond, CH₂, CH₂CH₂, CHR₉, CO, O, NH, NR₉; R₁ = R₁₀- and/or R₁₁-substituted Ph, heteroaryl, heteroaryl N-oxide, naphthyl; R₂ = R₁, R₁₀- and/or R₁₁-substituted fluorenyl or R₁₀-substituted C1-6-alkyl, C2-6-alkenyl, C3-6-cycloalkyl, adamantyl, C4-8-cycloalkenyl; R₃ = R₂; R₁XNR₃ = optionally R₁₀-substituted Z; A = CH₂, NH, NR₉, S, SO, SO₂, O; n = 0 - 2; R₄, R₆ = R₅, CN, OH, OR₉, F, Cl, Br, I; R₅, R₇ = H, C1-6-alkyl, C1-6-hydroxyalkyl, C2-6-alkoxyalkyl, C1-6-haloalkyl, Ph, CH₂Ph, heteroaryl; R₈ = H, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, Ph, CH₂Ph, CN, CH₂NH₂, CH₂NHR₉, CH₂N(R₉)₂, CH₂NHCO₂R₉, CH₂NR₉CO₂R₉, CH₂NHCONHR₉, CH₂NR₉CONHR₉, CH₂NR₉CON(R₉)₂, CH₂NHCO₂R₉, CH₂NR₉CO₂R₉, CH₂NHSO₂R₉, CH₂N(SO₂R₉)₂, CH₂NR₉SO₂R₉; R₉ = C1-6-alkyl, C3-6-cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, Ph, CH₂Ph, heteroaryl, CF₃] and their pharmaceutically acceptable salts, have interesting pharmaceutical properties, e.g., as CCR5 inhibitors. Piperidine derivs. I [R₁₀ = C1-6-alkyl, C1-6-hydroxyalkyl, C2-6-alkoxyalkyl, C1-6-haloalkyl, C3-6-cycloalkyl, C2-6-alkenyl, C2-6-cycloalkenyl, C2-6-alkynyl, Ph, heteroaryl, heteroaryl N-oxide, F, Cl, Br, I, OH, OR₉, CONH₂, CONHR₉, CON(R₉)₂, OC(:O)R₉, OCO₂R₉, OC(:O)NHR₉, OC(:O)NHR₉, OC(:O)N(R₉)₂, OSO₂R₉, CO₂H, CO₂R₉, CF₃, CHF₂, CH₂F, CN, NO₂, NH₂, NHR₉, N(R₉)₂, NHCOR₉, NR₉COR₉, NHCONHR₉, NHCONH₂, NR₉CONHR₉, NR₉CON(R₉)₂, NHCO₂R₉, NR₉CO₂R₉, NHSO₂R₉, N(SO₂R₉)₂, NR₉SO₂R₉, SiMe₃, B(OCMe₃); R₁₁ = two adjacent substituents which form an annulated 4 - 7 membered ring containing up to two heteroatoms of the group N, O, S; Y = bond, CO, COCH₂, SO, SO₂, CS, CH₂, C(CH₂CH₂), CHR₅, C(R₄)₂] have

interesting pharmaceutical properties, e.g., their use as chemokine receptors inhibitors. A process for the preparation of I comprises; (a) amidating I (YR2 = H) with R2Y'A' [Y' = CO, COCH2, SO, SO2]; A' = leaving group, e.g., Cl, Br, OH; (b) reductive amidation of I (YR2 = H); or (c) reacting I (XR1 = H) with R1X"-halogen (X" = CH2, CHR9). Thus, bipiperidinybenzamide II (Y = CO, R2 = C6H3Me2-2,6) was prepared from bipiperidinamine I (Y = bond, R2 = H) and 2,6-Me2C6H3COCl in DMF containing EtN(CHMe2)2 and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate. Bipiperidinamines I were tested as chemokine receptor inhibitors [IC50 = 2 - 3 nM vs. [I-125]MIP-1 α binding to human CCR5 membrane for I (R1 = R3 = Ph, R2 = C6H4Me2-2,6, R4 - R7 = H, R8 = Me, X = CH2, Y = C:O); IC50 = 10 μ M vs. Ca2+ mobilization for II; chemotaxis by I in presence of MIP-1 α , IC50 = \leq 1 μ M].

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 7

L10 HAS NO ANSWERS

'HITSTR ' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ----- Structure Image, Attributes, and map table if it contains data. (Default)

SIM ----- Structure Image.

SAT ----- Structure ATtributes and map table if it contains data.

SCT ----- Structure Connection Table and map table if it contains data.

SDA ----- All Structure DATA (image, attributes, connection table and map table if it contains data).

NOS ----- NO Structure data.

ENTER STRUCTURE FORMAT (SIA), SCT, SDA, SIM, SAT, NOS:end

=> d hitstr 19 7

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

IT 470689-17-9P 470689-20-4P 470689-21-5P

470689-23-7P 470689-27-1P 470689-32-8P

470689-43-1P 470689-57-7P 470689-60-2P

470689-61-3P 470689-72-6P 470689-77-1P

470689-78-2P 470689-79-3P 470689-81-7P


470689-85-1P 470689-86-2P 470689-90-8P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bipiperidiny-derivs. and their use as chemokine receptors inhibitors)


RN 470689-17-9 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 4'-methyl-1'-[(4-methyl-5-pyrimidinyl)carbonyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-20-4 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-21-5 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[(4,6-dimethyl-2-phenyl-5-pyrimidinyl)carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-23-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[[4,6-dimethyl-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-27-1 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[(4,6-dimethyl-1-oxido-5-pyrimidinyl)carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-32-8 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 4'-methyl-N,N-diphenyl-1'--[(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 470689-43-1 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[[4,6-dimethyl-2-(1-oxido-4-pyridinyl)-5-pyrimidinyl]carbonyl]-4'-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-57-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-60-2 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-1-oxido-5-pyrimidinyl)carbonyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-61-3 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[[4,6-dimethyl-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)




RN 470689-72-6 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 470689-77-1 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[(4,6-dimethyl-1-oxido-5-pyrimidinyl)carbonyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 470689-78-2 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[[4,6-dimethyl-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 470689-79-3 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[[4,6-dimethyl-2-(1-oxido-4-pyridinyl)-5-pyrimidinyl]carbonyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 470689-81-7 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-N-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 470689-85-1 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[(4,6-dimethyl-1-oxido-5-pyrimidinyl)carbonyl]-N-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 470689-86-2 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'--[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4'-methyl-N-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 470689-90-8 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, N-(4-bromophenyl)-1'--[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4'-methyl-N-phenyl- (9CI) (CA INDEX NAME)

